Cancer screening recommendations Book Section
| Author: | Latcha, S. |
| Editors: | Finkel, K. W.; Perazella, M. A.; Cohen, E. P. |
| Article/Chapter Title: | Cancer screening recommendations |
| Abstract: | Paraneoplastic glomerulopathy remains a rare clinical entity. Because glomerular disease can be the initial clinical manifestation of an underlying malignancy, the nephrologist may have a crucial role in initiating the evaluation for an underlying malignancy, and in doing so, avoid delays in the proper identification and treatment of a neoplasia. Paraneoplastic glomerular disease can present before, after or concurrent with the detection of an associated neoplasia. There is no clear consensus on whether all patients who present with a glomerular disease should be screened for an underlying malignancy. None of the national or international nephrology groups have offered or endorsed any cancer screening guidelines in patients with suspected paraneoplastic glomerulopathy. Populations who may be at risk for paraneoplastic glomerulopathy include older patients, those with a history of heavy tobacco use, unexplained proteinuria, those exposed to immunosuppressive medications and patients with membranous nephropathy on the renal biopsy. This chapter presents opinion-based recommendations for the cancer screening in patients with suspected paraneoplastic glomerulopathy. © 2020 Elsevier Inc. All rights reserved. |
| Keywords: | cancer risk; cancer screening; paraneoplastic glomerulopathy; cancer-related glomerular disease; cancer-related kidney disease |
| Book Title: | Onco-Nephrology |
| ISBN: | 9780323549455 |
| Publisher: | Elsevier Inc. |
| Publication Place: | Philadelphia, PA |
| Date Published: | 2020-01-01 |
| Start Page: | 225 |
| End Page: | 228.e1 |
| Language: | English |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Book Chapter: 24 -- Export Date: 2 November 2020 -- Source: Scopus |
MSK Authors
-
34Latcha
Related MSK Work